Skip to main content

Table 3 A comparison of survival outcome data

From: RandomiSed clinical trial assessing Use of an anti-inflammatoRy aGent in attenUating peri-operatiVe inflAmmatioN in non-meTastatic colon cancer – the S.U.R.G.U.V.A.N.T. trial

  Total
(n = 60)
Saline
(n = 28)
Taurolidine
(n = 32)
p-value
Overall recurrence 6 3 3 1
Recurrence at 2 years 3 2 1 0.389
Mean time to recurrence (months)   16.3 28.6 0.4
Median time to recurrence (months)   19 38 0.268